[go: up one dir, main page]

AR026102A1 - Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion - Google Patents

Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion

Info

Publication number
AR026102A1
AR026102A1 ARP990106171A ARP990106171A AR026102A1 AR 026102 A1 AR026102 A1 AR 026102A1 AR P990106171 A ARP990106171 A AR P990106171A AR P990106171 A ARP990106171 A AR P990106171A AR 026102 A1 AR026102 A1 AR 026102A1
Authority
AR
Argentina
Prior art keywords
polyethylene
pharmaceutical composition
solid form
mocrollide
purify
Prior art date
Application number
ARP990106171A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR026102(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR026102A1 publication Critical patent/AR026102A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Se refiere a un proceso para estabilizar un macrolildo de polieno, que comprende agregar un antioxidante al macrolido purificado, y a un macrolidoparticular obtenido en forma cristalina de la formula (1) y su proceso de purificacion; una mezcla en fo rma solida, una composicion farmacéutica.
ARP990106171A 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion AR026102A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds

Publications (1)

Publication Number Publication Date
AR026102A1 true AR026102A1 (es) 2003-01-29

Family

ID=26314797

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990106171A AR026102A1 (es) 1998-12-07 1999-12-03 Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
ARP050100744A AR048073A2 (es) 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene
ARP060101807A AR054444A2 (es) 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP050100744A AR048073A2 (es) 1998-12-07 2005-02-28 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene
ARP060101807A AR054444A2 (es) 1998-12-07 2006-05-04 Mezcla en forma solida de rapamicina o un derivado se rapamicina y un antioxidante

Country Status (38)

Country Link
US (5) US6605613B2 (es)
EP (4) EP1137439B2 (es)
JP (3) JP3805625B2 (es)
KR (2) KR20060096477A (es)
CN (2) CN1261163C (es)
AR (3) AR026102A1 (es)
AT (1) ATE365051T1 (es)
AU (1) AU759219B2 (es)
BE (1) BE1012869A3 (es)
BR (1) BR9915986A (es)
CA (3) CA2651609A1 (es)
CO (1) CO4980847A1 (es)
CY (1) CY1106870T1 (es)
CZ (2) CZ303006B6 (es)
DE (1) DE69936352T3 (es)
DK (1) DK1137439T4 (es)
ES (1) ES2288033T5 (es)
FR (1) FR2786771B1 (es)
GB (2) GB9826882D0 (es)
HK (1) HK1038889B (es)
HU (2) HU228939B1 (es)
ID (1) ID29250A (es)
IL (1) IL143092A0 (es)
IT (1) IT1319701B1 (es)
MY (2) MY127579A (es)
NO (2) NO332698B1 (es)
NZ (2) NZ511936A (es)
PE (1) PE20001333A1 (es)
PL (2) PL208854B1 (es)
PT (1) PT1137439E (es)
RU (1) RU2243769C2 (es)
SG (1) SG151072A1 (es)
SI (1) SI1137439T2 (es)
SK (2) SK287325B6 (es)
TR (2) TR200101416T2 (es)
TW (2) TWI270550B (es)
WO (1) WO2000033878A2 (es)
ZA (1) ZA200104360B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
JP4261365B2 (ja) 2002-02-13 2009-04-30 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 生物学的物質からのマクロライドの抽出方法
KR101131794B1 (ko) 2002-07-30 2012-03-30 와이어쓰 엘엘씨 Ｃｃｉ-779 공용매 농축액, 비경구 ｃｃｉ-779 제형 및 비경구 ｃｃｉ-779 제형의 제조방법
JP4468943B2 (ja) * 2003-03-31 2010-05-26 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ マクロライド系の結晶化及び精製
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
DK1558622T3 (da) 2003-07-24 2008-02-25 Teva Gyogyszergyar Zartkoeruee Fremgangsmåde til oprensning af macrolider
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005056103A1 (en) * 2003-12-10 2005-06-23 Acrux Dds Pty Ltd Method of treatment for undesired effect following transdermal or topical drug delivery
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
EP1809247A1 (en) * 2004-09-29 2007-07-25 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
PE20071000A1 (es) * 2005-12-07 2007-10-10 Wyeth Corp Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
JP2009520818A (ja) * 2005-12-20 2009-05-28 ワイス 薬物物質不純物の制御によるｃｃｉ−７７９製剤安定性の制御
JP5528708B2 (ja) * 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
WO2011156025A1 (en) * 2010-06-07 2011-12-15 Telik, Inc. Crystalline Ezatiostat Hydrochloride Ansolvate
JP5985474B2 (ja) * 2010-08-04 2016-09-06 メリル ライフ サイエンシズ ピーブィティ．エルティディ 抗増殖特性を有する新規４２−ｏ−（ヘテロアルコキシアルキル）ラパマイシン化合物の調製プロセス
US9079921B2 (en) 2010-11-19 2015-07-14 Biocon Limited Processes for preparation of Everolimus and intermediates thereof
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (es) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
WO2017018433A1 (ja) 2015-07-28 2017-02-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法
US20190015513A1 (en) * 2015-08-28 2019-01-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
EP3351245A4 (en) * 2015-09-18 2019-05-22 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
US11814397B2 (en) 2020-03-27 2023-11-14 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
CA1338150C (en) † 1988-02-18 1996-03-12 Edward George Howard, Jr. Ceramic/distillable binder compositions
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP0593227B1 (en) 1992-10-13 2006-03-22 Wyeth Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
RU2181054C2 (ru) * 1994-11-02 2002-04-10 Новартис Аг Микроэмульсионный предконцентрат
AU712193B2 (en) * 1995-06-09 1999-10-28 Novartis Ag Rapamycin derivatives
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DE69736750T2 (de) * 1996-07-30 2007-08-16 Novartis Ag Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
JP2001511780A (ja) 1997-02-04 2001-08-14 アボツト・ラボラトリーズ 鎮痛性非経口リポソーム配合物

Also Published As

Publication number Publication date
US6605613B2 (en) 2003-08-12
KR20060096477A (ko) 2006-09-11
ZA200104360B (en) 2002-01-16
NO334612B1 (no) 2014-04-22
JP5165199B2 (ja) 2013-03-21
AU759219B2 (en) 2003-04-10
US20020032213A1 (en) 2002-03-14
CA2732620C (en) 2013-08-06
JP2005200429A (ja) 2005-07-28
NO20012424D0 (no) 2001-05-16
EP2269651A2 (en) 2011-01-05
EP1137439A2 (en) 2001-10-04
NZ527781A (en) 2004-11-26
WO2000033878A2 (en) 2000-06-15
TWI270550B (en) 2007-01-11
JP2002531527A (ja) 2002-09-24
TR200101416T2 (tr) 2002-01-21
CZ303006B6 (cs) 2012-02-22
SG151072A1 (en) 2009-06-29
EP1743657A3 (en) 2007-03-28
US20050107418A1 (en) 2005-05-19
HU230174B1 (hu) 2015-09-28
IT1319701B1 (it) 2003-10-27
EP1137439B2 (en) 2011-11-23
AR054444A2 (es) 2007-06-27
WO2000033878A3 (en) 2000-11-02
TR200201428T2 (tr) 2002-12-23
MY127579A (en) 2006-12-29
SI1137439T2 (sl) 2012-05-31
ES2288033T5 (es) 2012-04-10
EP1137439B1 (en) 2007-06-20
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
CN1876657A (zh) 2006-12-13
EP2279751A3 (en) 2011-02-16
NO20012424L (no) 2001-05-16
PL196627B1 (pl) 2008-01-31
US20030191148A1 (en) 2003-10-09
ES2288033T3 (es) 2007-12-16
HU228939B1 (en) 2013-07-29
CA2651609A1 (en) 2000-06-15
CZ20012001A3 (cs) 2001-09-12
DK1137439T4 (da) 2012-03-19
KR100695834B1 (ko) 2007-03-19
DE69936352T2 (de) 2008-02-14
RU2243769C2 (ru) 2005-01-10
PT1137439E (pt) 2007-09-25
US7572804B2 (en) 2009-08-11
SK286688B6 (sk) 2009-03-05
JP2006111637A (ja) 2006-04-27
ID29250A (id) 2001-08-16
GB9904934D0 (en) 1999-04-28
CA2351580C (en) 2012-03-20
FR2786771B1 (fr) 2002-12-27
NO20121113L (no) 2001-05-16
HK1038889B (en) 2008-01-25
DE69936352T3 (de) 2012-05-03
GB9826882D0 (en) 1999-01-27
EP2269651A3 (en) 2011-03-09
PE20001333A1 (es) 2000-12-12
US6852729B2 (en) 2005-02-08
CA2351580A1 (en) 2000-06-15
US20090270441A1 (en) 2009-10-29
TW200540179A (en) 2005-12-16
CN1876657B (zh) 2013-01-09
ATE365051T1 (de) 2007-07-15
CA2732620A1 (en) 2000-06-15
AU1657300A (en) 2000-06-26
JP3805625B2 (ja) 2006-08-02
EP1743657A2 (en) 2007-01-17
CO4980847A1 (es) 2000-11-27
ITMI992520A1 (it) 2001-06-02
PL348333A1 (en) 2002-05-20
HUP0104489A3 (en) 2004-05-28
FR2786771A1 (fr) 2000-06-09
HK1038889A1 (en) 2002-04-04
AR048073A2 (es) 2006-03-29
PL208854B1 (pl) 2011-06-30
TWI248938B (en) 2006-02-11
US7297703B2 (en) 2007-11-20
ITMI992520A0 (it) 1999-12-02
CN1261163C (zh) 2006-06-28
US20080161334A1 (en) 2008-07-03
DE69936352D1 (de) 2007-08-02
BR9915986A (pt) 2001-09-04
CZ302210B6 (cs) 2010-12-22
EP2279751A2 (en) 2011-02-02
IL143092A0 (en) 2002-04-21
CN1374872A (zh) 2002-10-16
SK7662001A3 (en) 2001-12-03
US7741338B2 (en) 2010-06-22
SK287325B6 (sk) 2010-07-07
NO332698B1 (no) 2012-12-10
HUP0104489A2 (hu) 2002-03-28
MY120594A (en) 2005-11-30
BE1012869A3 (fr) 2001-04-03
NZ511936A (en) 2003-10-31
SI1137439T1 (sl) 2008-06-30
KR20010101128A (ko) 2001-11-14
JP5043308B2 (ja) 2012-10-10

Similar Documents

Publication Publication Date Title
AR026102A1 (es) Un proceso para estabilizar un mocrolido de polietileno, una mezcla de forma solida, una composicion farmaceutica, un derivado de rapamicina y un procesopara su purificacion
DK1268471T3 (da) N-heterocykliske derivater som NOS-inhibitorer
PT915898E (pt) Forma i cristalina de claritromicina
EA199901016A1 (ru) 9-оксим-производные эритромицина
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
NL350075I2 (es)
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
DE69830504D1 (de) Antithrombotische mitteln
BR0212345A (pt) Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor de ácido de bile ileal em um animal de sangue quente e composição farmacêutica
BR9803887A (pt) Macrociclos.
BR0212277A (pt) Composto, processo para preparar um composto, uso de um composto, método para produzir um efeito inibidor do ibat, e, composição farmacêutica
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
UY26199A1 (es) Nuevos derivados de benceno, un procedimiento para su preparación y las composiciones farmacéuticas que los contienen
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
BR0109975A (pt) Método para produzir ansamitocinas
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
AR025951A1 (es) Derivados de 4-hicroxibifenil hidrazidas y métodos para preparar los derivados.
ATE344230T1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
AU4424401A (en) Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
SV1998000013A (es) Derivados de 5-aroilnaftaleno ref.-ran 4070\115
BRPI0207102A8 (pt) forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso

Legal Events

Date Code Title Description
FG Grant, registration